Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-3630
- Development stage
- Preclinical
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
mRNA-3630 is an investigational messenger RNA (mRNA) vaccine candidate developed by Moderna to prevent infection by the protozoan parasite *Toxoplasma gondii*. The vaccine utilizes Moderna's proprietary lipid nanoparticle (LNP) technology to deliver mRNA sequences that encode for specific antigens of the parasite. Upon administration, host cells translate the mRNA into proteins that mimic the parasite's surface or secreted proteins, thereby stimulating both humoral (antibody) and cellular (T-cell) immune responses. This approach aims to provide protection against primary infection and potentially prevent the reactivation of latent toxoplasmosis, which is particularly dangerous for immunocompromised individuals and during pregnancy, where it can lead to congenital toxoplasmosis.
- Other names
- Toxoplasmosis vaccine
Beyond the preview
Go deeper on mRNA-3630.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-3630.